In particular, in a PTEN loss context, increased activity of the PI3K-β isoform [102] and the efficacy of PI3K-β isoform inhibition, by specific targeted agents (GSK2636771, AZD8186) [103], could overcome the resistance mechanisms to immune targeted agents, as reported for example in melanoma patients [66]. Here, PPIB is linked to melanoma.